Clinical Trials Browser

Phase 1/2 × PEGPH20 × Breast × Clear all

NCT02753595 2020-07-13

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Phase 1/2 Terminated

25 enrolled 9 charts

Breast Neoplasms